Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma

Advances in the molecular biology of medulloblastoma revealed four genetically and clinically distinct subgroups. Group 3 medulloblastomas are characterized by frequent amplifications of the oncogene MYC, a high incidence of metastasis, and poor prognosis despite aggressive therapy. We investigated several potential small molecule inhibitors to target Group 3 medulloblastomas based on gene expression data using an in silico drug screen. The Connectivity Map (C-MAP) analysis identified piperlongumine as the top candidate drug for non-WNT medulloblastomas and the cyclin-dependent kinase (CDK) inhibitor alsterpaullone as the compound predicted to have specific antitumor activity against Group 3 medulloblastomas. To validate our findings we used these inhibitors against established Group 3 medulloblastoma cell lines. The C-MAP predicted drugs reduced cell proliferation in vitro and increased survival in Group 3 medulloblastoma xenografts. Alsterpaullone had the highest efficacy in Group 3 medulloblastoma cells. Genomic profiling of Group 3 medulloblastoma cells treated with alsterpaullone confirmed inhibition of cell cycle-related genes, and down-regulation of MYC. Our results demonstrate the preclinical efficacy of using a targeted therapy approach for Group 3 medulloblastomas. Specifically, we provide rationale for advancing alsterpaullone as a targeted therapy in Group 3 medulloblastoma.

[1]  Filip Pattyn,et al.  Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds , 2009, Clinical Cancer Research.

[2]  R. Eisenman,et al.  N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. , 2002, Genes & development.

[3]  J. Rutka,et al.  Aurora kinase B/C inhibition impairs malignant glioma growth in vivo , 2012, Journal of Neuro-Oncology.

[4]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[5]  Benjamin L Ebert,et al.  The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2. , 2010, Cancer research.

[6]  Paul A. Northcott,et al.  Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma , 2009, Nature Genetics.

[7]  F. Zindy,et al.  Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. , 2003, Cancer research.

[8]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[9]  J. Jacobberger,et al.  Inhibition of Cdk1 by Alsterpaullone and Thioflavopiridol Correlates with Increased Transit Time from Mid G2 Through Prophase , 2004, Cell cycle.

[10]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[11]  F. Zindy,et al.  Hemangiosarcomas , Medulloblastomas , and Other Tumors in Ink 4 c / p 53-null Mice 1 , 2003 .

[12]  Michael D. Cole,et al.  Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors , 2003, Development.

[13]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[14]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[15]  W. Lam,et al.  Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor. , 2012, Cancer genetics.

[16]  K. Mikoshiba,et al.  Cyclin-dependent kinase 5 is required for normal cerebellar development , 2013, Molecular and Cellular Neuroscience.

[17]  D. Rowitch,et al.  Development of mice expressing a single D-type cyclin. , 2002, Genes & development.

[18]  S. Pfister,et al.  MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma , 2011, Acta Neuropathologica.

[19]  Canguo Zhao,et al.  Expression-Based In Silico Screening of Candidate Therapeutic Compounds for Lung Adenocarcinoma , 2011, PloS one.

[20]  Conrad Kunick,et al.  Alsterpaullone, a novel cyclin‐dependent kinase inhibitor, induces apoptosis by activation of caspase‐9 due to perturbation in mitochondrial membrane potential , 2003, Molecular carcinogenesis.

[21]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[22]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[23]  M. Hatten,et al.  Cerebellum development and medulloblastoma. , 2011 .

[24]  T. Golub,et al.  Selective killing of cancer cells with a small molecule targeting stress response to ROS , 2011, Nature.

[25]  Ming Zhao,et al.  Alsterpaullone, a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells through Apoptosis-Inducing Effect , 2013, Journal of analytical methods in chemistry.

[26]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[27]  K. Millen,et al.  Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation , 2006, Development.

[28]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[30]  A. Tward,et al.  Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC , 2007, Nature Medicine.

[31]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Rowitch,et al.  Sonic hedgehog Promotes G1 Cyclin Expression and Sustained Cell Cycle Progression in Mammalian Neuronal Precursors , 2000, Molecular and Cellular Biology.

[33]  R. Beroukhim,et al.  BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.